Salbutamol: A Safety Meta-Analysis

Salbutamol: A Safety Meta-Analysis Overview Salbutamol, a widely used bronchospasm reliever, has been insufficiently scrutinized for potential risks. In a meta-analysis of 58 randomized controlled trials with 12,961 participants, the study unearthed a 34% incidence of total adverse events (AEs). Notably, severe AEs stood at 2%, and treatment discontinuation was 3%. Subgroup

Renal Cell Carcinoma- Prognosis via Albumin Levels

Renal Cell Carcinoma- Prognosis via Albumin Levels Metastatic renal cell carcinoma (mRCC) - An Introduction Renal cell carcinoma (RCC) constitutes approximately 90% of all urologic malignancies. Approximately 30% of patients with RCC present with metastatic disease, and amongst those with localized disease, a substantial proportion will recur. Before 2005, immunotherapy with interleukin-2

Salbutamol: A Safety Meta-Analysis